

BAXTER INTERNATIONAL INC.
Key Product Line Sales by US and International
Periods Ending December 31, 2007 and 2006
(unaudited)
(\$ in millions)

	Q4 2007			Q4 2006 ¹			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants ²	\$205	\$258	\$463	\$191	\$214	\$405	7%	21%	14%
Plasma Proteins ³	112	189	301	102	160	262	10%	18%	15%
Antibody Therapy	199	81	280	158	49	207	26%	65%	35%
Regenerative Medicine ⁴	50	45	95	43	35	78	16%	29%	22%
Other ⁵	13	57	70	15	75	90	(13%)	(24%)	(22%)
Total BioScience⁶	\$579	\$630	\$1,209	\$509	\$533	\$1,042	14%	18%	16%
Medication Delivery									
IV Therapies ⁷	\$117	\$273	\$390	\$113	\$228	\$341	4%	20%	14%
Global Injectables ⁸	219	171	390	234	140	374	(6%)	22%	4%
Infusion Systems	141	95	236	132	89	221	7%	7%	7%
Anesthesia ⁹	83	43	126	64	28	92	30%	54%	37%
Other ¹⁰	4	9	13	6	5	11	(33%)	80%	18%
Total Medication Delivery	\$564	\$591	\$1,155	\$549	\$490	\$1,039	3%	21%	11%
Renal									
PD Therapy	\$71	\$410	\$481	\$67	\$362	\$429	6%	13%	12%
HD Therapy	29	91	120	28	80	108	4%	14%	11%
Total Renal	\$100	\$501	\$601	\$95	\$442	\$537	5%	13%	12%
Baxter excluding Transfusion Therapies	\$1,243	\$1,722	\$2,965	\$1,153	\$1,465	\$2,618	8%	18%	13%
Transfusion Therapies¹¹	\$31	\$13	\$44	\$78	\$67	\$145	(60%)	(81%)	(70%)
TOTAL BAXTER	\$1,274	\$1,735	\$3,009	\$1,231	\$1,532	\$2,763	3%	13%	9%

1 Prior year data has been reclassified to reflect the changes that are described in Notes 2, 5, 6, 8, 9 and 11 below.

2 Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE). Sales of recombinant FIX (BeneFIX) were previously reported in Recombinants and are now reported in Other, as detailed below.

3 Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, and certain other plasma-based products.

4 Previously referred to as BioSurgery.

5 Principally includes vaccines, sales of plasma to third parties, and recombinant FIX (BeneFIX). Sales of recombinant FIX were previously reported in Recombinants.

6 BioScience sales have been reclassified to reflect the change described in Note 11.

7 Principally includes intravenous solutions and nutritional products.

8 Principally includes sales related to the pharmaceutical partnering business, enhanced packaging, premix drugs and generic injectables. Generic injectables were previously reported in Anesthesia.

9 Principally includes proprietary inhaled anesthetics and other anesthesia products. Sales of generic injectables were previously reported in Anesthesia and are now reported in Global Injectables.

10 Principally includes other hospital-distributed products.

11 The Transfusion Therapies (TT) business was sold on February 28, 2007. The results of operations of the TT business were previously reported in the BioScience business. Due to Baxter's actual and expected significant continuing cash flows associated with this business, Baxter continued to include the results of operations of the TT business in the company's results of continuing operations through the divestiture date. The TT totals above include sales of TT products through the date of divestiture, as well as post-divestiture revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business post-divestiture.